Nature Communications (Jun 2020)
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer
Abstract
Phosphodiesterase-5 (PDE5) inhibitors have been suggested to have an anti-tumor effect and block surgery-induced immunosuppression. Here, the authors show that postdiagnostic use of PDE5 inhibitors is associated with a decreased risk of colorectal cancerspecific mortality as well as a decreased risk of metastasis.